Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Grosses $112.7M in IPO With Over-Allotment Option

This story has been updated from a previous version to correct the amount of the gross proceeds from Nanosphere's IPO and the over-allotment.
 
NEW YORK (GenomeWeb News) - Nanosphere yesterday said it completed its initial public offering of 7 million shares, and that its underwriters have exercised their full over-allotment option to buy an additional 1.05 million shares at $14 apiece, bringing gross proceeds to $112.7.
 
The company, which trades under the ticker symbol NSPH, in August said it generated $1.1 million in revenues last year and $1.9 million in revenues in 2005, and held $34.5 million in cash and cash equivalents as of March 31.
 
The molecular diagnostics company’s sole book-runner was Credit Suisse Securities. Co-managing the IPO were Piper Jaffray & Co., Leerink Swan, and Allen & Company.
 
In Wednesday morning trade on the Nasdaq, Nanosphere's shares were down $.21 at $20.79.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.